Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis by Bohanec Grabar Petra, Grabnar Iztok, Rozman Blaz, Logar Dusan, Tomsic Matija, Suput Dasa, Trdan Tina, Peterlin Masic Lucija, Mrhar Ales, Dolzan Vita in Drug metabolism and disposition: the biological fate of chemicals (2009).

[PMID: 19581389] PubMed


Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.